Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.84 USD
Change Today -0.0141 / -1.66%
Volume 187.6K
OCLS On Other Exchanges
Symbol
Exchange
OCLS is not on other exchanges.
As of 8:10 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

oculus innovative sciences i (OCLS) Key Developments

Oculus Innovative Sciences Announces Launch of MicrocynAH(R) Farm and Ranch Animal Healthcare Products

Oculus Innovative Sciences, Inc. announced the introduction of two new MicrocynAH® Farm and Ranch animal healthcare products. Intended for care of traumatic wounds, cuts abrasions, skin irritations, skin ulcers, post-surgical incisions, burns, scratches, rashes and irritated skin, both the MicrocynAH® Farm and Ranch Spray and the MicrocynAH® Farm and Ranch Hydrogel are manufactured with the original patented Microcyn® Technology.

Oculus Innovative Sciences, Inc. Receives Non-Compliance Notice From NASDAQ

On March 6, 2015, Oculus Innovative Sciences, Inc. received a letter from the Listing Qualifications staff of The NASDAQ Stock Market LLC, notifying the company that, for the last 30 consecutive business days, the company failed to comply with NASDAQ Listing Rule 5550(a)(2), which requires to maintain a minimum bid price of $1.00 per share for common stock. In accordance with Listing Rule 5810(c)(3)(A), NASDAQ granted the company a compliance period of 180 calendar days, or until September 2, 2015, to regain compliance with the Listing Rule. If at any time during this 180 day period the closing bid price of the common stock is at least $1 for a minimum of 10 consecutive business days, the company will regain compliance with the Listing Rule and NASDAQ will close the matter. The letter has no effect on the listing or trading of the common stock at this time. However, there can be no assurance that the company will be able to regain compliance with Listing Rule 5550(a)(2). The company intends to cure the bid price compliance deficiency by effecting a reverse stock split, if necessary.

Oculus Innovative Sciences, Inc. Announces Launch of New Animal Healthcare Division

Oculus Innovative Sciences, Inc. announced the launch of the company's new animal healthcare division. In conjunction with the unveiling of the new division, six new MicrocynAH® advanced all-animal healthcare products were commercialized for the care of wounds, skin and eyes in the United States and Canadian markets.

Oculus Innovative Sciences, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014; Reports Impairment for the Third Quarter Ended December 31, 2014

Oculus Innovative Sciences, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended December 31, 2014. For the third quarter of fiscal year 2015, the company’s total revenue was $3.2 million for the third quarter as compared to $3.3 million for the same period in 2013. Net loss was $5.9 million, an increase of $5.3 million, as compared to net loss of $611,000 for the same period in the prior year. The increase is primarily due to an impairment loss recorded in the three months ended December 31, 2014, in the amount of $4,650,000, related to Oculus' investment in Ruthigen. Loss from operations was $1,949,000 compared to $1,546,000 a year ago. Net loss per common basic and diluted share was $0.69 compared to $0.09 a year ago. For the nine months, the company’s total revenues were $9.9 million, as compared to $10.8 million for the same period in the prior year. Loss from operations was $5,007,000 compared to $3,943,000 a year ago. Net loss was $6,702,000 or $0.79 per basic and diluted share, compared to $3,722,000 or $0.56 per basic and diluted share, a year ago. The company reported impairment for the third quarter ended December 31, 2014. For the third quarter, the company reported loss on impairment of investment held at cost of $4,650,000.

Oculus Innovative Sciences, Inc. to Report Q3, 2015 Results on Feb 12, 2015

Oculus Innovative Sciences, Inc. announced that they will report Q3, 2015 results at 1:30 PM, Pacific Standard Time on Feb 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCLS:US $0.84 USD -0.0141

OCLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,925 JPY -9.00
Henry Schein Inc $139.99 USD -2.55
Integra LifeSciences Holdings Corp $60.75 USD -0.56
Patterson Cos Inc $47.37 USD -0.82
Smith & Nephew PLC 1,157 GBp -11.00
View Industry Companies
 

Industry Analysis

OCLS

Industry Average

Valuation OCLS Industry Range
Price/Earnings 9.3x
Price/Sales 0.6x
Price/Book 0.9x
Price/Cash Flow 16.8x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCULUS INNOVATIVE SCIENCES I, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.